Literature DB >> 32124676

Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?

Omar Abdel-Mannan1, Rosa Cortese2, Evangeline Wassmer3, Cheryl Hemingway4, Alan Thompson5, Wallace Brownlee2, Olga Ciccarelli6, Yael Hacohen1.   

Abstract

Previous cohort studies on paediatric multiple sclerosis (MS) have reported very low frequencies for a primary progressive MS (PPMS) course ranging from 0% to 7%. We identified six patients presenting prior to the age of 18 years and fulfilling the 2017 McDonald Criteria for PPMS. Presentation with progressive neurological symptoms and signs in young people should prompt evaluation for genetic causes such as leukodystrophies, hereditary spastic paraparesis and mitochondrial diseases given the rarity of primary progressive course in paediatric MS. In the absence of an alternative diagnosis, with new therapeutic options becoming available for PPMS, this diagnosis should then be considered.

Entities:  

Keywords:  MS mimics; McDonald criteria; Primary progressive multiple sclerosis; disease modifying therapies; paediatric multiple sclerosis

Mesh:

Year:  2020        PMID: 32124676     DOI: 10.1177/1352458520910361

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

1.  Confirming a Historical Diagnosis of Multiple Sclerosis: Challenges and Recommendations.

Authors:  Andrew J Solomon; Georgina Arrambide; Wallace Brownlee; Anne H Cross; María I Gaitan; Fred D Lublin; Naila Makhani; Ellen M Mowry; Daniel S Reich; Àlex Rovira; Brian G Weinshenker; Jeffrey A Cohen
Journal:  Neurol Clin Pract       Date:  2022-06

2.  Personalized Disease Monitoring in Pediatric Onset Multiple Sclerosis Using the Saliva Free Light Chain Test.

Authors:  Esther Ganelin-Cohen; Evgeny Tartakovsky; Ely Klepfish; Sizilia Golderman; Ayal Rozenberg; Batia Kaplan
Journal:  Front Immunol       Date:  2022-04-05       Impact factor: 8.786

3.  Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.

Authors:  Arlette L Bruijstens; Katelijn M Blok; Joost Smolders; Beatrijs Ha Wokke; Rinze F Neuteboom
Journal:  Mult Scler       Date:  2020-05-14       Impact factor: 6.312

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.